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Abstract 
Tolerated by normal tissues, anti-cancer therapies based on titanium compounds are 
limited by low efficacy/selectivity and lack of understanding of their mode(s) of action. 
In vitro antitumour activity and mode of cell death incurred by enantiopure TiCl2{-
C5H4CHEt(2-MeOPh)}2 (abbreviated Cp
R
2TiCl2) has been investigated. The in vitro 
anti-tumour activity of Cp
R
2TiCl2 is selective for cancer cells; in clonogenic assays, 
(S,S)-Cp
R
2TiCl2 was twice as effective at inhibiting colony formation than other 
stereoisomers after 24 h exposure. HPLC, MS and NMR techniques determined 
hydrolysis of Cp
R
2TiCl2; data strongly correlate with soluble [Cp
R
2Ti(OH)(OH2)]
+
 being 
the biological trigger. Treatment of cells with Cp
R
2TiCl2 provoked extensive 
cytoplasmic vacuolization, endoplasmic reticulum (ER) swelling and activation of 
MAPKinase signal transduction, consistent with ligand-induced paraptosis, type III cell 
death, which is morphologically distinct from, and independent of apoptosis. Indeed, 
distinct from cisplatin, Cp
R
2TiCl2 failed to perturb cell cycle dynamics, induce γH2AX 
foci or evoke apoptosis in MDA-MB-468 and HCT-116 cells.  
 
Titanocenes ǀ chiral cyclopentadienyls ǀ paraptosis ǀ cancer ǀ MDA-MB-468 
 
Introduction 
Pioneering work more than 30 years ago revealed the antiproliferative properties of 
titanocene dichloride (Cp2TiCl2; 1) and analogous titanocene complexes
1
 in tumour models in 
vitro and in vivo.  Cp = η-C5H5 is a cyclopentadienyl ligand; Cp2TiCl2 was the first non-
platinum coordination complex and the first metallocene to be investigated as an anticancer 
drug. It underwent phase 1 clinic trials in adults with advanced solid tumors in 1993
2,3,4
. 
Although Cp2TiCl2 was tolerated, dose-limiting adverse reactions, attributed to 
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nephrotoxicity, hypoglycemia and nausea were encountered; however, the absence of 
myelosuppression, a common chemotherapeutic dose-limiting toxicity was intriguing, 
enhancing the medical applicability of this agent. Low antitumour efficacy in Phase 2 studies 
discouraged further development of this agent
5, 6
. 
Interest in titanocenes has been renewed with synthesis and evaluation of novel 
analogues exemplified by [{η-C5H4(CH2C6H4OCH3)}2TiCl2] (titanocene Y, 3) which 
demonstrated anticancer efficacy in human xenograft studies
7
. Substituted chiral titanocenes 
(e.g. 4) are thought to offer even greater efficacy but are seldom used due to inherent 
formation of mixures of stereoisomeric titanium complexes which complicates their study 
(Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cyclopentadienyls and titanocenes discussed in this paper. For titanoncene Y: Ar = 
4-MeOC6H4. For our own chiral titanocene 4: Ar = 2-MeOC6H4; R = Et; the chiral centres of 
4 are show by ‘*’. 
The anticancer mechanisms of titanocene dichloride complexes are not fully 
understood. It has been conjectured that activity is attributable to the compounds` interactions 
with the protein transferrin
8-11
. It has also been suggested that DNA may be the target for 
titanocene-based agents as titanium-DNA adducts were detected in A2780 cells treated with 
titanocene dichloride
12
.  However, experiments have indicated alternative mechanisms of 
action and cell death following detection of ligand-bound Ti(IV) complexes to other proteins 
(e.g. albumin) or proteolytic enzymes
13, 14
. Recently described has been the potent and 
selective anticancer activity of organometallic-titanocene compounds, but lack of interaction 
between compounds and plasmid DNA implicated alternative biomolecular targets; 
accordingly, AKT and MAP kinase family protein kinase activity was inhibited
15
.  
Ti
Cl
Cl
cyclopentadienyl
Cp
mono substituted
cyclopentadienyl
Cpr
Ar
chiral substituted
cyclopentadienyl
CpR
Ar
R Ti
Cl
Cl
Ar
Ar
R
R
4
1
In
cr
ea
si
n
g
 A
n
ti
ca
n
ce
r 
A
ct
iv
it
y
*
*
*
Ti
Cl
Cl
ansa bridged 
cyclopentadienyl
CpA
2
Ar
Ar
Ti
Cl
Cl
3
Ar
Ar
Ar
Page 2 of 23Metallomics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
M
et
al
lo
m
ic
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
18
 Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ot
tin
gh
am
 o
n 
18
/0
1/
20
16
 1
6:
44
:3
2.
 
View Article Online
DOI: 10.1039/C5MT00297D
3 
 
Hydrolytic instability in titanocenes, a consequence of initial loss of chloride, and 
potentially cyclopentadienyl-Ti cleavage, can provide a cocktail of species which is further 
complicated in chiral substrates. Multiple stereoisomers result unless single enantiomers of 
the chiral cyclopentadienyl ligands are used. Disentangling the relative biological activities of 
such mixtures is not normally possible. Recently, the enantio-enriched cyclopentadienyl 
fragment C5H4CHEt(2-MeOPh) (abbreviated Cp
R
) needed for the synthesis of enantiopure 
(S,S)-4 was attained by unprecedented copper-catalyzed asymmetric ZnEt2 addition to the 
exo-alkene of pentafulvene
16
. Such catalytic stereoselective addition of organometallics to 
pentafulvenes was previously unknown, preventing ready access to the desired biological 
probes.  
Herein we describe in vitro biological and biophysical studies of separated (R,R)- and 
(S,S)-4 enantiomers (Figure 1); determining whether cyclopentadienyl hydrolysis, and hence 
Ti
4+
 formation, is a prerequisite for biological activity; a question of contemporary interest
17
.  
 
Results and Discussion 
Biology 
MTT assays were used to determine growth inhibitory properties of (S,S)- and (R,R)-4 
enantiomers. Preliminary data revealed statistical (P<0.05) differential growth inhibitory 
activity following 24 h exposure of cancer cells to the enantiopure agents (S,S) vs. (R,R)-4
16
. 
However, after 72 h treatment, negligible selectivity between the stereoisomers of 4 was 
observed (Table 1). Intriguingly following 72 h treatment, all isomers of 4 demonstrated 
significant selectivity (between 2- and 5-fold; P<0.05) for cancer cell lines screened (e.g. 
GI50<6 µM; MDA-MB-468) over non-transformed MRC5 fibroblasts (GI50>25 µM). Such 
behavior raises questions concerning the aqueous speciation of 4 as a function of time (see 
biophysics later). The behavior of 4 is in contrast to cisplatin which showed no selectivity 
towards cancer cells (equipotency against Mia PaCa-2, HCT-116 carcinoma cells and MRC-5 
fibroblasts; with GI50 6-8 µM; Figure S1, 72 h). 
 
Table 1. Effect of Titanocene analogues and cisplatin in growth of carcinoma cells and 
fibroblasts in culture. Cells were exposed to test agent for 72 h before cell growth was 
determined by MTT assay. Mean GI50 values (M) were calculated from ≥3 independent 
trials (n = 8 per trial). 
      
 
 
 
 
Cell line 
GI50 value (µM) mean ± SD 
(R,R)-4 (S,S)-4 (rac/meso)-4 Cisplatin 
MiaPaCa-2 7.3  ± 0.5 5.7  ± 1.3 7.5  ± 0.4 5.8  ± 0.7 
MDA-MB-468 5.6  ± 1.8 5.4  ± 1.3 5.3  ± 1.7 2.1  ± 0.6 
HCT 116 14.0 ± 2.1 9.4  ± 1.2 12.2  ± 3.9 7.9  ± 0.5 
MRC5 25.1  ± 3.5 28.3  ± 5.0 28.6  ± 3.7 8.3  ± 3.1 
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Assays testing subsequent colony growth following 24 h exposure of single HCT 116 or Mia 
PaCa-2 cells to (S,S) or (R,R)-4 (20-50 M) support 2× differential enantiomer activity. For 
example, compared to control, 22% vs 46% HCT 116 survival and subsequent colony 
formation was determined in cells exposed to (S,S)-4 and (R,R)-4 (24 h) respectively (Figure 
2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of cisplatin and titanocene derivatives on HCT 116 and Mia PaCa-2 cell 
survival and colony formation following 72 h exposure to test agent. Colonies were fixed, 
stained and counted (n=6); 2 independent trials. *p<0.05 significant difference from control; 
2 way ANOVA, multiple comparisons.  
 
Cell cycle analyses, γH2AX foci and apoptosis 
Examination of cell cycle distribution revealed that in stark contrast to cisplatin, 
titanium based (S,S)-4 negligibly perturbed MDA-MB-468 or HCT 116 cell cycle (±5% of 
control values; Figure 3).  
 After 24 h treatment (MDA-MB-468; (S,S)-4), gap 2 and mitotic (G2/M) events were 
marginally elevated, but at 72 h exposure, negligible increases in pre-gap 1 (G1) and G1 
populations were encountered at the expense of G2/M events. Only after 72 h exposure of 
MDA-MB-468 cells to 20 µM (S,S)-4 was a minor increase (≤5%) in sub-G1 events detected. 
Cisplatin however (10 µM; 24 h and 72 h) caused significant accumulation of pre-G1 phase 
events (e.g. 28% and 60% total MDA-MB-468 population respectively). In HCT 116 cells, 
(S,S)-4 (20 µM; 72 h) did not increase the sub-G1 population, the only notable change was a 
slight decrease in S phase events – the period during which DNA is copies (DNA synthesis). 
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Cisplatin, in contrast, evoked significant and marked rises in G2/M phase events in HCT 116 
cells (24 h and 72 h; 15 µM and 25 µM); at 72 h, substantially significant subG1 events were 
detected (indicative of apoptosis; Figures 3 and 4Ciii).  
G2/M arrest would be expected of a DNA-damaging agent and cisplatin is known to 
form DNA intra-strand cross links, mono-adducts, inter-strand crosslinks, and DNA-protein 
crosslinks. Mostly it acts on adjacent N-7 guanine forming 1, 2 intra-strand crosslinks
18,19
. 
HCT 116 cells possess wild type P53, a tumour suppressor gene whose protein product has 
key roles in DNA damage detection, cell cycle arrest and DNA repair, or apoptosis initiation 
in the face of irreparable DNA damage
20
.  MDA 468 cells harbour mutant P53; in these cells, 
we fail to detect G2/M cell cycle arrest, however, hugely significant preG1 populations 
emerge. It may be surmised that in the absence of functional P53 and G2/M arrest, DNA 
repair mechanisms are not initiated and the preG1 populations observed following treatment 
of cells are indicative of apoptosis. Following treatment of cells with titanocene (S,S)-4 , 
significant cell cycle perturbation was clearly absent (Figure 4Cv), therefore there is no 
evidence to suggest titanocene 4 causes DNA damage resulting in apoptosis induction. 
Titanocene Y (3) has been reported to reduce clonogenic survival, cause DNA damage 
and dose-dependent apoptosis in prostate cancer cells, but did not affect the cell cycle
21
. 
O`Connor et al. report that 3 caused significant prostate cell cycle effects and apoptosis
22
.  
However, these authors concluded a caspase-independent mode of cell death when the pan 
caspase inhibitor ZVAD-FMK failed to inhibit apoptosis. Titanocene dichloride 1 triggered 
A2780 ovarian carcinoma cell cycle arrest in late S, early G2 cell cycle phase, formation of 
Ti-DNA adducts and apoptosis
12
. To determine whether (S,S)-4 caused DNA damage leading 
to double strand breaks (DSBs), we investigated generation of γH2AX. Histone H2AX is 
phosphorylated by kinases (such as ATM and ATR) at sites of DNA DSBs 1:1
23
.   
Dual γH2AX / cell cycle analyses further corroborated the thesis that titanocene 
analogue 4 failed to evoke DNA damage resulting in double strand breaks. In neither MDA-
MB-468 nor HCT 116 cells exposed for 72 h to 10 µM or 20 µM (MDA-MB-468) 20 µM or 
30 µM (HCT 116) (R,R)-4 or (S,S)-4 were significant γH2AX foci generated (Figure 4A and 
B). In contrast, significant DNA damage was detected in cells (MDA-MB-468 or HCT 116) 
exposed to cisplatin (5 µM; 10 µM or 15 µM; 25 µM respectively; P<0.05)). Particularly 
striking were the numbers of γH2AX positive events within the G2/M cell cycle phase of 
cisplatin treated HCT 116 populations (exemplified in Figure 4Ciii and iv; 15 µM; 72 h). 
Contrast this with the γH2AX (and cell cycle) profile of HCT 116 cells exposed to 30 µM 
(S,S)-4; 72 h, which is indistinct from control (Figure 4Cv and vi).  
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Figure 3. Effects of cisplatin, (R,R)-4 and (S,S)-4 on MDA-MB-468 and HCT 116 cell 
cycle distribution. Data represent ≥3 independent trials (n=2 per trial; 20,000 events analyzed 
per sample). *p<0.05 significant difference from control; 2 way ANOVA, multiple 
comparisons. In contrast to cisplatin which significantly increases preG1 cell cycle events, 
titanocenes (R,R)-4 and (S,S)-4 fail to dramatically perturb cell cycle distribution. 
 
DNA detected in the subG1 cell cycle phase is indicative of caspase-mediated 
apoptosis. SubG1 MDA-MB-468 and HCT 116 events were evident following exposure of 
cells to cisplatin; small but significant subG1 populations were observed in MDA-MB-468 
cells exposed to 10 µM (S,S)-4; 72 h. To determine whether apoptosis had been induced, cells 
were subject to dual PI/annexin V staining before analyses by flow cytometry. An early event 
during apoptosis is loss of membrane asymmetry. Phosphatidylserine (resident on the inner 
cell membrane leaflet) becomes exposed and binds annexin V. As apoptosis progresses to late 
phase, membrane integrity is lost allowing cell membrane penetration of PI.  
Bannon et al. demonstrated cell cycle perturbation and late apoptotic A431 epidermoid 
carcinoma cell populations following exposure to cisplatin or titanocene Y (3; 50 µM; 48 
h)
24
, indicative of caspase-induced apototosis. Similarly, gene expression analysis in small 
cell lung cancer cells treated with related species was in accord with DNA damage being the 
apoptosis trigger
25
. 
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Figure 4. Determination of DNA double strand breaks by flow cytometric analyses of 
γH2AX cells following 72 h treatment of A) MDA-MB-468 or B,C) HCT 116 cells with 
cisplatin, (R,R)-4 and (S,S)-4 enantiomers. Data represent ≥3 independent trials (n=2 per trial; 
20,000 events analyzed per sample). *p<0.05 significant difference from control; 2 way 
ANOVA, multiple comparisons. C) Representative analyses of HCT 116 cells demonstrating 
concurrent cell cycle distribution (i, iii, v) and γH2AX positive events (ii, iv, vi) following 
exposure of cells to vehicle (i, ii), 15 µM cisplatin (iii, iv) or 30 µM (S,S)-4 (v. vi).   
As is shown in Figure 5, cisplatin (5 µM and 15 µM) triggered significant MDA-MB-
468 and HCT 116 cellular apoptosis (60% and 30% respectively; P<0.05), consistent with 
cell cycle predictions. In contrast, following 72 h exposure of cells to (R,R)-4 and (S,S)-4 
titanocene enantiomers, significant annexin V+ (apoptotic) populations were detected only in 
MDA 468 cells treated with 20 µM (S,S)-4 and (R,R)-4. Again, corroborating cell cycle 
analyses, cells undergoing titanocene-induced apoptosis represented a minority population 
(<10%).  
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Based on our evidence, the hypothesis that (R,R)-4 and (S,S)-4 evoke anticancer 
activity, DNA damage and cell death through apoptosis was rejected. Indeed, features 
characteristic of apoptosis – chromatin condensation, nuclear fragmentation, cytoplasmic 
shrinkage, apoptotic membrane blebbing, formation of apoptotic bodies – were absent (TEM, 
confocal microscopy). However, other dramatic cellular morphological modifications were 
induced by 4 (the timing of which was concurrent with maximized concentrations of 
intermediate [Cp
R
2Ti(OH)(OH2)]
+
; <6 h; as explained later). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effects of cisplatin and titanocene derivatives on MDA-MB-468 (A, C) and HCT 
116 (B, D) apoptosis. Cells were exposed to test agent for 72 h and prepared for flow 
cytometric analyses following dual annexin V, PI staining. A, B) Cells undergoing apoptosis 
were defined as the sum of early apoptotic (annexin V +ve) and late apoptotic (annexin V 
+ve, PI +ve) populations. Data represent ≥3 independent trials (n=2 per trial; 20,000 events 
analyzed per sample). *p<0.05 significant difference from control; 2 way ANOVA, multiple 
comparisons. Representative analyses of MDA-MB-468 (C) and HCT 116 (D) apoptotic 
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populations following 72 h exposure of cells to: i) vehicle; ii) 15 µM cisplatin; iii) 20 µM 
(R,R)-4; iv) 30 µM (R,R)-3; v) 20 µM (S,S)-4; vi) 30 µM (S,S)-4.   
Induction of Paraptosis 
Titanocene 4 induced rapid (<6 h), distinctive changes in cellular morphology; 
extensive cytoplasmic vacuolization became evident in cells exposed to (S,S)-4 (20 M - 0-
13 h. Confocal microscopy time-image studies of live MDA-MB-468 cells reveal ER 
swelling (0.33-66 h, Figure S4A) and crater-like cups on the cell surface (Supplementary 
Information movie; Figure 6A). This is followed by vacuole membrane rupture (osmotic 
lysis) and cell death. After the highest practical exposure of MDA-MB-468 cells to 
(rac/meso)-4 (50 M, 3-6 h) that did not result in immediate cellular rupture, TEM Z-
Contrast sections (Figure 6B) reveal the generation of numerous low density vesicles (Figures 
6B and S3-S6) within the cytoplasm characteristic of type III cell death – paraptosis, a 
primitive form of programmed cell death dependent upon protein transcription and 
translation, mediated by MAP kinase signaling
26
. 
Consistent with MAP kinase signal transduction, (S,S)-4 (20 µM) strongly increased 
expression of total and phosphorylated EGFR (1 h – 24 h) in lysates of treated MDA-MB-468 
cells (Figure 6C). After 12 h and 24 h exposure, powerfully up-regulated phosphorylated and 
total ERK 1 and 2 expression was also evident (Figures 6C and D). Screening lysates of 
MDA-MB-468 cells treated with (S,S)-4 (20 M) for 24 h against an array of key kinases 
corroborated strong up-regulation of ERKs 1 and 2 (Figure 6D). In HCT-116, AKT 
overexpression is observed in both cisplatin and titanocene 4 treated cells (24 h) which could 
be indicative of attempted survival in this cell line
27
. AKT signaling networks cascade to 
ERK1/2; indeed, in HCT 116 cells, following treatment with titanocene 4 only was up-
regulation of both phosho ERK1/2 (at 3 h and 6 h) and total ERK 1/2 (6, 12 and 24 h) 
detected. 
The ERK cascade represents a central signaling pathway regulating distinct and 
opposing cellular processes
28,29
.  Herein, we propose that activation of receptor-mediated 
signal transduction leads directly to cell death through over production of the observed 
vacuoles and eventual membrane rupture. Such events are known to be triggered by selective 
activation of range of receptor-mediated pathways
26,30,31
 in different cell types. MDA-MB-
468 carcinoma cells, isolated from a patient with metastatic breast carcinoma represent a 
triple negative cell line expressing high levels of EGFR
32
. HCT 116 harbor mutant RAS 
rendering the MAP kinase cascade constitutively active
33
.    
 
Park et al. report vacuolization and dilated ER and mitochondria in MH-S murine alveolar 
macrophages by TiO2 nanoparticles, and conclude that induced paraptosis and late onset 
apoptosis are the modes of action
34
. This may to be related to the cellular toxicity we observe, 
at 72 h exposure for samples rich in insoluble titanium compounds, but cannot account fully 
for the selective toxicity we see for the soluble intermediate ≤24 h. 
Such behavior might be expected if hydrolysis of 4 is stepwise: chlorides initially (fast) 
and then, potentially, cyclopentadienyl units (slow) affording ‘ligand-less’ Ti-species whose 
subsequent uptake (endocytosis) is not enantiomer dependent.  Endocytosis of TiO2 20-30 nm 
nanospheres (after 24 h) in breast cancer SK-BR-3 cells is reported, resulting in average 
titanium concentrations of 28±5 picomols per cell as determined by ICP-MS, with some 
individual cells showing burdens >1000 picomol
35
. However, MDB-MB-468 breast cells 
treated with (S,S)-4 (30 M/3 h; the highest dose-time achievable without extensive lysis) 
revealed average titanium burdens per cell of only 3.3±0.3 femtomol (compared to 0.35 
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femtomol for control, untreated cells). To specifically address the possibility that 4 is 
degraded to simple Ti
4+ 
salts, its hydrolysis in dilute solution was studied and modeled by 
HPLC, MS and NMR techniques. 
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Figure 6. Paraptosis (type III cell death) induced by 4 in MDA-MB-468 and HCT 116 cells. 
A) Confocal microscopy MDA-MB-468 live cell imaging time-series studies after exposure 
to (S,S)-4 (20 M) revealed cytoplasmic vacuolization and ER swelling, followed by vacuole 
membrane rupture (osmotic lysis) and cell death. B) TEM imaging of MDA-MB-468 cells 
after exposure to (rac/meso)-4 (50 µM; 3-6 h), revealed extensive vacuolization. C) Western 
blot assays of MDA-MB-468 and HCT-116 lysates following treatment of cells with (S,S)-4 
(20 or 30 M; 1-24 h) or cisplatin (15 or 20 µM; 1, 6, 24 h). D) Lysates of MDA-MB-468 
cells were subjected to the human phospho-MAPK array screen. Up-regulation of 
phosphorylated ERK1 and ERK2 was observed following treatment of cells with (S,S)-4 (24 
h; 20 µM).   
 
Biophysics 
The unsubstituted cyclopentadienyl complex Cp2TiCl2 (1) forms 
[Cp2Ti(OH)n(OH2)m](Cl
-
)2-n mixtures (n = 1 - 2, n + m = 2) undergoing deprotonation / 
reprotonation events  upon dissolution in aqueous media
36
. Hydrolytic Ti-Cp cleavage also 
occurs leading to poorly characterized, mixtures of Ti-complexes and free CpH. Correlation 
of biological effects to individual aquated titanium complexes is thus not practical for 1.  It is 
suggested that titanocenes containing monosubstituted cyclopentadienyls (specifically 3; 
titanocene Y), are totally resistant to Ti-C5H4R hydrolysis
37
 potentially simplifying the 
number of aqueous Ti-species present. However, to the best of our knowledge, no definitive 
data have been published to support such assertions. Thus, we studied the aqueous dissolution 
behavior of 4 under conditions close to the biological and imaging studies above (0-72 h and 
μM aqueous concentrations) by HPLC, MS and NMR techniques.  
Initial biological screening stock solutions (20 mM) of 4 were attained by dissolution in 
DMSO at room temperature. The 800 MHz 
1
H NMR spectra of both rac and meso-4 (200 
μM) in d6-DMSO is very similar to that in anhydrous non-coordinating CDCl3 (average 
signal shift +0.1 ppm; deviation range on individual signals: +0.0 to +0.5 ppm) and invariant 
over 48 h. Chiral HPLC analyses of such solutions provide only elution of (R,R)-, (S,S)- or 
meso-4 bands (correlating with the sample used and identical with authentic samples). These 
observations strongly suggest no ionization of chloride or Cp
R
 groups takes place in DMSO 
prior to dilution with RPMI medium to give 200 μM samples of 4 containing 1% v/v aqueous 
d6-DMSO. The latter nominal 200 μM aqueous samples, while appearing clear to the naked 
eye, contain colloidal suspensions of 4 on the basis that: (i) unfiltered samples give a +ESI 
MS signal at m/z 509 with a 
35/37
Cl isotope pattern for [(Cp
R
)2TiCl]
+
 (for 4 - Cl), which is 
absent in equivalent filtered or HPLC eluted samples. (ii) Model dilution of 20 mM (S,S)-4 in 
                  Control                                                    (S,S)-4 (20 µM; 24 h) 
P-ERK1                    P-ERK2 
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d6-DMSO to 200 μM in D2O provides 
1
H 800 MHz initial NMR spectra that are broad and 
characteristic of undissolved material (Supplementary Information). On standing, 200 μM 
colloidal suspensions of (S,S)-4 in RPMI lead to formation of a new homogeneous 
intermediate I as evidenced by its elution in LCMS (tr 3.0 min). The intermediate I ionizes as 
m/z 491 which was assigned to [Cp
R
2Ti(OH)]
+
. Treatment of solutions containing the 
intermediate I with methanol led to immediate qualitative formation of a signal at m/z 505 in 
+ESI MS. Such behavior is consistent with [Cp
R
2Ti(OMe)]
+
 formation through solvent 
exchange. Over time the concentration of the [Cp
R
2Ti(OH)]
+
 I intermediate in 1% v/v 
DMSO/RPMI first maximizes (tmax = 1.2 h) and then decays, over 24 h, with re-formation of 
an insoluble colloid based on reduction of signal intensity in the LCMS analysis.  Analysis of 
the unfiltered residue reveals a +ESI MS signal at m/z 981 assigned as [2 × Cp
R
2Ti(O)+H
+
]. 
The formation of intermediate I could be modeled by dissolution of (R,R)-4 to nominal 200 
μM in 1% v/v d6-DMSO/D2O at room temperature. The initial insolubility of (S,S)-4 was 
confirmed, as was the generation (and subsequent decay, t½ ~ 1.7 h) of the same soluble 
intermediate I (also ionizing as m/z 491/492). When the concentration of intermediate I is 
maximized (ca. 80 μM) the 800 MHz 1H NMR spectrum is fully in accord with the presence 
of a ‘CpR2Ti’ core with no cyclopentadienyl cleavage (Figure 7A). The soluble intermediate’s 
kinetic behavior could also be modelled by consecutive equilibrating first order reactions 
simulating both the growth of I and its subsequent decay well (Figure 7B, quality of fit R
2
 
0.98, see Supplementary Information). The hypothesis that I is Lewis acidic [Cp
R
2Ti(OH)]
+
 
and that it can bind external ligands (H2O and other donor ligands) was tested by additional 
runs in 20% v/v d6-DMSO:D2O. The lifetime of the intermediate increased 5-fold (t½ ~9.5 h, 
with increased maximum intermediate concentration of 200 M). This supports Lewis base 
exchange forming [Cp
R
2Ti(OH)(DMSO)]
+
 at increased DMSO concentration. However in 
1% v/v DMSO/aqueous conditions all evidence (HPLC, MS, NMR) supports 
[Cp
R
2Ti(OH)(H2O)]Cl as the identity of the major aqueous species I (>90%) present during 
the observation of enantiomer differentiated paraptosis. The decay of I is apparently due to 
deprotonation leading to neutral product (Cp
R
)2Ti=O which is not soluble in water – rather 
than hydrolysis to non Cp
R
 containing species. Both I’s kinetic behavior (apparent 
equilibrium with an insoluble product) and observation of traces of its dimerization product 
[{(Cp
R
)2Ti=O}2+H]
+
 m/z 981 in the +ESI MS are in accord with this hypothesis. Importantly, 
within the time periods employed in our experiments (0-60 h) we could detect no free Cp
R
H 
hydrolysis products (down to 1-2 M) in NMR experiments – indicating that the situation for 
4 is very different to that of the parent 1. The overall behavior of 4 upon aqueous dilution and 
ions detected by MS and LCMS during the starting material (colloidal), intermediate (truly 
homogeneous) and product (colloidal) phases of the hydrolyses of (S,S)-4 are summarized in 
Figure 8. 
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Figure 7. A) Partial 
1
H NMR spectrum (6-7.5 ppm) of the truly homogeneous intermediate I 
(ca. 80 mM) resulting from dissolution of 4 in 1:99 d6-DMSO/D2O. Signals attributable other 
functional groups within I could also be detected: IH 7.33, 7.18, 7.10, 7.03 (Hb) 6.63, 6.48, 
6.08 (2H) (CHC5H4), 3.84 (OMe), 1.90, 1.80 and 0.71 (3H) (Et) (see SI). Traces of meso-
diasteriomer (m) can also be seen in the spectrum as the rac/meso ratio of the (R,R)-4 (>99:1 
e.r.) used was 85:15. The broad signal at H 7.28 grows in with formation of I and may 
indicate aggregation before precipitation of insoluble product (P). B) Fit of the concentration 
of I vs. time after first dissolution of colloidal (R,R)-4 nominally 200 mM in 1:99 d6-
DMSO/D2O to equilibrating first order reactions using the equations of Moore and Pearson. 
 
 
Figure 8. Observed and inferred processes on dissolution of 4 in aqueous media. 
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The lack of free Cp
R
 in cultures containing 4, very low Ti intracellular concentrations 
and enantiomer dependent biology are not in accord with significant accretion of 
cyclopentadienyl free Ti
4+
 within our cell lines. Such suggestions originally arose from 
exposure of dead tissue samples to massive excesses of 1 and in apparent low level EELS Ti 
signals detected in biopsy samples
38,39
. In reproducing the latter we find the titanium EELS 
signal is reproducibly coincident with a background artefact, and at best, low Ti 
concentrations are present with no aggregation of TiO2-like species above 1 nm diameter 
within MDA-MB-468 cells detectable (3-6 h) (Supplementary Information). Transferrin has 
been suggested as mechanism for Ti
4+
 transport into cells
40,25
, but recent studies
41
 show it had 
no significant positive effect on the anti-cancer activity of 1 and other Ti-based agents. If 
titanium transport into MDA-MB-468 does operate in our system the resultant aggregates 
would have to be both very small (<1 nm) and numerous (>10
10
) per cell to avoid our 
detection limits. In known paraptotic TiO2-triggered systems the Ti-particles are typically 5-
500 nm in size
34,42
 and these would have been detected by our equipment. Based on the low 
levels of titanium per cell, the alternative possibility of titanium-based paraptotic signal 
transduction makes perfect sense. Indeed, evidence of signal transduction pathways activated 
to produce cytoplasmic induced paraptosis by (S,S)-4 is presented herein. Conversely, slow 
endocytosis of colloidal Cp
R
2Ti(O), precipitated from soluble I over time, would also be fully 
concordant with the lack of enantiomer recognition we see at 72 h when screening 4 in MTT 
assays. Finally, exchange of [Cp
R
2(OH)(H2O)]
+
 I to longer lived [Cp
R
2Ti(OMe)(MeOH)]
+
 
also provides a rational for the, otherwise poorly explained, increased toxicity of 1 when it is 
pre-treated with methanol
43
.  
In summation, in the period during which paraptosis was observed, soluble m/z 491 
[Cp
R
2Ti(OH)]
+
 was the only cyclopentadienyl intermediate observed (>90% of total signal). 
No free ligand m/z 214 was detected in LCMS studies ≤24 h. Addition of MeOH to solutions 
containing m/z 491 [Cp
R
2Ti(OH)]
+
 led to its rapid complete conversion to m/z 505 
[Cp
R
2Ti(OMe)]
+
. All of these observations are in accord with [Cp
R
2(OH)(H2O)]
+ 
I being the 
major solution species present under conditions leading to biological activity. 
 
Conclusions 
(S,S)-4, (R,R)-4 and (rac,meso)-4 revealed growth inhibitory activity with equivalent 
potency to cisplatin in mammary, colorectal and pancreatic carcinoma cell lines. Unlike 
cisplatin, selectivity (2-5-fold) for cancer cell lines over MRC5 fibroblasts was detected. Low 
tissue (and myesosuppressive) toxicity (compared with Pt-based drugs) would render 
titanocene anticancer agents candidates for combination therapy. 
In clonogenic assays, survival and colony formation after 24 h exposure demonstrated 
enantiomer selectivity: (S,S)-4 2-fold greater potency, corroborating previous MTT assays 
performed following 24 h exposure of cancer cell lines to titanocene 4 enantiomers
16
. 
In stark contrast to cisplatin, titanocene 4 negligibly perturbed MDA-MB-468 and HCT 
116 cell cycle, did not cause DNA double strand breaks and failed to trigger significant 
apoptosis. Evidence strongly advocates cell death by paraptosis following treatment of cancer 
cells to titanocene 4: extensive cytoplasmic vacuolization accompanied by up-regulated 
expression of proteins integral to EGFR, MAP kinase and AKT signal transduction preceded 
membrane rupture and cell death. Appearance of these dramatic cellular morphological 
modifications is concurrent with maximized concentrations of a soluble intermediate I whose 
NMR, MS and kinetic behavior is concordant with [Cp
R
2Ti(OH) )(H2O)]
+
. 
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The history of titanocene dichloride thereaputic agents is populated with conflicting 
suggestions for biological pathways that have subsequently proved tangential to modes of 
action in particular cell lines. Unpicking the specific biological chaperone(s) that bind(s) the 
key hydroxyl active intermediate triggering paraptosis will require extensive systematic 
correlation of target binding to cancer cell growth inhibition across a wide family of 
enantiomeric substituted titanocenes to ensure complete veracity of the biological target(s) 
involved. This is the next goal of our research. However, we can conclude that the single 
enantiomeric titanocenes are highly appropriate and powerful tools for such approaches, and 
may herald the possibility of titanocene-based therapy through paraptosis. 
 
Methods. 
Test agents 
Titanocene enantiomers 4 were synthesized according to a recently published method
16
. 
Cisplatin was purchased from Sigma-Aldrich. 
Cell culture 
Cells were passaged twice weekly upon reaching 70-80% confluency. Cells were sub-
cultured in RPMI 1640 medium containing sodium bicarbonate supplemented (2 g/L), L-
glutamine (0.3 g/L) and 10% heat-inactivated foetal bovine serum (FBS). 
MTT assay 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay was used as 
described
44
 to assess the ability of test agents to inhibit cell growth and/or evoke cytotoxicity. 
MTT assays were performed at the time of agent addition (T zero) and following 72h 
exposure of cells to test agents. 
 
Clonogenic assay 
The clonogenic cell survival test was adopted to measure the ability of a single cell to survive 
brief exposure to test agent and maintain proliferative potential to form progeny colonies.  
The assay was performed as previously described
44
. 
 
Cell cycle analysis 
Cell cycle analyses were performed according to Nicoletti et al
45
. Cells were seeded in cell 
culture dishes at densities of 3-5×10
5
 cells/dish in 10 mL medium. Following treatment, cells 
were harvested and pelleted by centrifugation then re-suspended in 0.5-1 mL fluorochrome 
solution (50 µg/mL propidium iodide (PI), 0.1 mg/mL ribonuclease A, 0.1% v/v Triton X-
100, and 0.1% w/v sodium citrate in dH2O). Cells were stored overnight in the dark at 4 
o
C. 
Cell cycle analyses were performed on a Beckman Coulter FC500 flow cytometer. EX- PO32 
software was used to analyze data. 
 
Dual determination of γH2AX foci and cell cycle perturbation 
For dual γH2AX detection of DNA double strand breaks and cell cycle analysis cells were 
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seeded in cell culture dishes at densities of 3-5×10
5
 cells/dish in 10 mL medium. Following 
72 h treatment, cells were harvested and pelleted by centrifugation, re-suspended and washed 
(2x) in PBS, pelleted by centrifugation and fixed in 500 µL 1% methanol-free formaldehyde 
in PBS (5 min; room temperature). Cells were permeabilized by adding 500 µL 0.4% Triton-
X-100in PBS. FBS (1% in PBS; 1 mL) was added to cells with gentle mixing before 
incubation at room temperature for 30 min. Cell suspensions were centrifuged and 
supernatants aspirated. 1
o
 Ab solution (200 µL) was added to each tube and samples were 
incubated for 1.5 h. PBS (1 mL) was added and samples were centrifuged and supernatants 
discarded. 2
o
 Ab was introduced (200 µL) and samples incubated for 1 h at room temperature 
before addition of 1 mL PBS. Samples were centrifuged and supernatant again discarded. 
Cells were resuspended in PBS containing 300 µL 50 µg/mL PI and 0.1 mg/mL RNaseA. 
Analyses of cells by flow cytometry followed >10 min incubation. 
Annexin V apoptosis assay 
Reagents used were Annexin V-FITC Ab, 1× annexin binding buffer (1:10 dilution 10× 
annexin binding buffer in dH2O), and PI solution (50 µg/mL in PBS). Cells (1×10
5
 cells/well) 
were seeded in 6 well plates are incubated overnight before treatment with test agent (24 and 
72 h). Cells were trypsinised and collected in FACS tubes then kept on ice for 10 min. 
Annexin-V-FITC (5μL) plus 100 μL 1× annexin-V buffer were added to cells after 
centrifugation. After 15 min incubation in the dark at room temperature, PI (10 μL; 50 μg/mL 
in PBS) plus 400 μL annexin-V buffer were added. Samples were protected from light and 
kept on ice for 10 min before analysis on a Beckman Coulter FC500 flow cytometer. EX- 
PO32 software was used to analyze data. 
 
Confocal microscopy 
MDA-MB-468 cells (3×10
5
) were seeded over coverslips in glass petri dishes in 2 mL RPMI 
supplemented with 10% FBS. Cells were incubated at 37 
o
C for 24 h, to allow attachment, 
prior to titanocene 4 exposure (3-6 h). Medium was aspirated, cells washed (2×; HBSS) and 
DNA stained (4 µM Hoeschst; 37 oC; 30 min). Solution was aspirated, cells washed and re-
stained with 1 µM ER-Tracker red for 20 min. Staining solution was aspirated, cells washed 
and bathed in medium before viewing by fluorescence confocal microscopy (Zeiss LSM710 
confocal instrument; Zeiss observer with PlanApo 40x/1.30 oil objective. Images were 
captured running Zen software. 
Transition electron microscopy 
A JEOL 2100F TEM instrument equipped with Gatan Orius high sensitivity cameras was 
used. Atomic contrast HAADF imaging was performed using the JEOL Digital STEM 
system and Electron Energy Loss Spectroscopy (EELS) was via a Gatan Tridiem Filter. The 
TEM was also equipped with a state-of-the-art windowless X-MaxN 100TLE EDX detector. 
The system was equipped with a Gatan 914 liquid nitrogen cooled holder, for stabilizing 
heat-sensitive samples.  
 
This configuration allowed analysis on the nm scale at concentrations ≥0.01% for the typical 
sample thickness and acquisition time used in this study. Concentrations of Ti 1 part in 
10,000 C, or Ti content aggregates > 1nm would be detected if present within the cell.  
MDA-MB-468 cells were cultured in thermanox coverslips in 6 well plates. Cells were 
allowed to attach for 24 h before exposure to 50 µM 4 ≤6 h. In order to achieve maximum 
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dose-time exposure and to maximize the opportunity for uptake and detection of titanium, 
meso/rac-4 was used. Untreated control cells and titanocene treated cells were fixed with 3% 
EM Glutaraldehyde in 0.1 M cacodylate buffer for 1 h at 4 
o
C. Fixed cells were then washed 
with 0.1 M cacodylate buffer followed by post-fixation with 1% aqueous osmium tetroxide 
for 30 min. Samples were washed with dH2O for 5 min followed by serial dehydration in 
ethanol (50%; 70%; 90%; 100%). The coverslips were then transferred to a clean porcelain 
dish and washed (2 x 5 min) with 100% propylene oxide. Resin (25 mL araldite CY212 resin, 
15 mL agar 100 resin, 55 mL DDSA, 2 mL dibutyl phthalate and 1.5 mL DMP 30) was 
prepared and samples were infiltrated with this resin mixture.  Samples were then embedded 
by inverting the coverslip on a ballistic electron emission microscopy (BEEM) capsule filled 
with the resin so that only the cell layer was embedded in the resin. The sample was then left 
in an embedding oven for 48 h at 60 
o
C. The resin sample was then sectioned using an 
ultramicrotome (200 nM thickness) and embedded in a copper mesh grid and stained with 
uranyl acetate/lead citrate.  
Imaging and elemental analysis in the TEM was performed on microtomed sections, both on 
sections supported on copper mesh grid only – i.e. sample against vacuum – or on sections 
additionally supported on newly commercially available graphene oxide support grids (Agar 
Scientific). The graphene oxide films provide a charge and heat conductive support that 
stabilizes the sample under the electron beam, allowing longer acquisition times
46
.  
 
Inductively coupled plasma mass spectrometry (ICP-MS) 
Cells were grown as described in 5 mL RPMI-1640 medium supplemented with 10% FBS. 
No titanium above background levels (0.3 ppb) could be detected in either component. 
Typically, 5 × 105 MDA-MB-468 cells were grown in the presence of (S,S)-4 (30 M), or 
vehicle control. Higher concertation-time loadings of (S,S)-4 could not be used without 
engendering degradative lysis. Following 4 h exposure, growth media were removed to 
separate vials and cells were washed with 2 × 2 mL PBS, and the wash buffer was added to 
the appropriate vials containing the separated supernatant medium. The remaining cells were 
then trypsinized (1mL) and pelleted by centrifugation; the supernatant trypsin solution was 
added to the appropriate wash vial. The cell pellet was once more washed (PBS; 1 mL). 
Pelleted cells were digested (16% w/w HNO3, 3 mL, 95 
o
C, 2 h) and diluted with MilliQ 
water to a final volume of 15 mL. The combined wash solutions were similarly digested. 
Analyses were conducted on a Thermo Scientific iCAP QC. 
 
Western blot 
MDA-MB-468 and HCT 116 cells were seeded in dishes (100×20 mm) at a density of 1-2 x 
10
6
 per dish, allowed 24 h to attach, and exposed to test agent (1 – 24 h). Following required 
exposure, cells were lysed in NP-40 lysis buffer supplemented with PhosSTOP Phosphatase 
Inhibitor Cocktail (Roche Applied Science) and COMPLETE-mini Protease Inhibitor 
Cocktail (Roche Applied Science). Cell debris was removed by centrifugation at 14,000 x g 
for 5 min. Protein concentrations were determined using QuickStart Bradford Assay (Bio-
Rad, Hemel Hempstead, UK). Cell lysate proteins (50 μg) were separated by SDS-
polyacrylamide gel electrophoresis and then transferred to a nitrocellulose membrane. 
Membranes were probed with the following antibodies, all purchased from Cell Signaling 
Technologies:  p-EGFR (Tyr1068), total-EGFR, p-AKT (Ser473), total-AKT, p-GSK3β 
(Ser9), total-GSK3β, p-ERK1/2(Thr202/Tyr204), total-ERK1/2 and GAPDH. 
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Relative protein phosphorylation 
Relative protein phosphorylation levels of 24 kinases were detected simultaneously using the 
Human Phospho-Mitogen-activated Protein Kinase (MAPK) Antibody Array (Catalog # 
ARY002B) from R&D systems according to the manufacturer’s instructions. Briefly, MDA-
MB-468 cells were seeded in Corning® tissue-culture treated culture dishes (100 mm x 20 
mm; 1 x 10
6 
per culture dish). Cells were allowed to attach overnight and left untreated or 
treated with (S,S)-4, 20 μM, for 24 h. Cells were rinsed with PBS followed by solubilization 
in lysis buffer by gently rocking at 4°C for 30 min. Cell lysates were then microcentrifuged at 
14,000 x g for 5 min and then the supernatant was transferred into a clean eppendorf tube.  
Quantitation of sample protein concentration was carried out using QuickStart Bradford 
Assay (Bio-Rad, Hemel Hempstead). Aliquots of the lysates were then stored frozen at −80 
°C. Membranes were blocked with the kit’s blocking buffer at room temperature for 1 h on a 
rocking platform shaker. Whilst membrane blocking, the 2 cell lysate samples (MDA-MB-
468 – 24 h control and 24 h (S,S)-4 20 μM) were diluted with array buffer followed by a 
cocktail of biotinylated detection Abs. The sample was mixed and incubated at room 
temperature for 1 h. The sample/antibody mixture was placed on the membrane and the dish 
containing the membrane was incubated overnight at 4°C on a rocking platform shaker. 
Thereafter, cocktails of biotinylated detection antibodies were added at room temperature for 
1 h. Phosphorylated proteins were revealed using streptavidin-HRP/Chemi Reagent Mix and 
autoradiography films (Amersham Hyperfilm ECL, GE Healthcare Life Sciences, 
Buckinghamshire, UK). 
 
NMR spectroscopy 
Samples of (S,S)- or (R,R)-4 (200 μM in D2O/d6-DMSO, 99:1) for combined 800 MHz NMR 
were prepared as described for preparation of stock solutions of 4 used in biological and MS 
studies, except that D2O, not RPMI-1640, was used. Attempts to directly study samples in 
RPMI-1640 led to the observation of very broad signals. For NMR studies (R,R)-4 (0.6 mg, 
1.1 μmol) was dissolved in spectroscopic grade d6-DMSO (55 μL) to afford a nominal 20 
mM top stock solution. An aliquot of this (15 μL, 0.3 μmol) was added to 1485 μL standard 
solution (67 μM) of Na-TMSP-d4 [3-(trimethylsilyl)-2,2',3,3'-tetradeuteropropionic acid, 
sodium salt] in D2O and the time noted. A sample of this nominal 200 μM solution of (R,R)-4 
containing Na-TMSP-d4 internal standard (67 μM) was immediately transferred to the 800 
MHz spectrometer and the latter set to attain 
1
H NMR spectra every 25 min (probe 
temperature 25±0.2 
o
C). The limit of detection of soluble species was ~1 μM. Controlled 
spiking experiments with Cp
R
H confirmed identification of free ligand at 1 M, but none was 
detected in the period of observation (0-60 h).  
Mass Spectrometry 
In a manner identical to preparation of sample dilutions for biological studies, 200 μM (S,S)-4 
was prepared in RPMI-1640 (pH 6.9 to 7.2) using freshly prepared 20 mM DMSO top stock. 
Mass spectrometry provided insight into species derived from (S,S)-4. Liquid 
Chromatography Mass Spectrometry (LCMS) assayed only truly homogeneous species (fine 
colloidal suspensions, even those apparently clear to the naked eye, are not eluted making this 
a powerful way to separate genuine solution Cp
R
Ti species from degradation events). Direct 
injection of sample for Electrospray Mass Spectrometry (ESMS) allowed detection of both 
homogeneous and colloidal species. Ions from the latter could be identified by the presence 
of extra signals in the paired mass spectra. 
Page 19 of 23 Metallomics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
M
et
al
lo
m
ic
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
18
 Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f N
ot
tin
gh
am
 o
n 
18
/0
1/
20
16
 1
6:
44
:3
2.
 
View Article Online
DOI: 10.1039/C5MT00297D
20 
 
LCMS was carried out using an Agilent 1260 Infinity HPLC with a 6120 Quadrupole mass 
spectrometer. A Waters Sunfire C18 3.5μm 2.1 x 30 mm column was used; mobile phase 1 
comprised 0.1% formic acid in water; mobile phase 2 comprised 0.1% formic acid in 
acetonitrile. Experiments were performed at 40 
o
C with a flow rate of 0.8 mL min
-1
, gradient 
5-95 % mobile phase 2 over 3.5 minutes with UV detection at 210-400 nm reported at 254 
nm. MS ionisation by ESI operated in positive ion mode. Samples were collected every 10 
min ≤ 6 h depending on the rate of change in the speciation. Direct ESMS was conducted on 
a Bruker microTOF instrument in 1% DMSO in D2O. 
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